Keller JN - Search Results

1

Intrinsic differences in brain and spinal cord mitochondria: Implication for therapeutic interventions.

Sullivan PG, Rabchevsky AG, Keller JN, Lovell M, Sodhi A, Hart RP, Scheff SW. Sullivan PG, et al. Among authors: keller jn. J Comp Neurol. 2004 Jul 5;474(4):524-34. doi: 10.1002/cne.20130. J Comp Neurol. 2004. PMID: 15174070

2

Brain injury and tumor necrosis factors induce calbindin D-28k in astrocytes: evidence for a cytoprotective response.

Mattson MP, Cheng B, Baldwin SA, Smith-Swintosky VL, Keller J, Geddes JW, Scheff SW, Christakos S. Mattson MP, et al. J Neurosci Res. 1995 Oct 15;42(3):357-70. doi: 10.1002/jnr.490420310. J Neurosci Res. 1995. PMID: 8583504

3

RNA in brain disease: no longer just "the messenger in the middle".

Nelson PT, Keller JN. Nelson PT, et al. Among authors: keller jn. J Neuropathol Exp Neurol. 2007 Jun;66(6):461-8. doi: 10.1097/01.jnen.0000240474.27791.f3. J Neuropathol Exp Neurol. 2007. PMID: 17549006 Review.

4

Interplay between oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease.

Keller JN. Keller JN. J Biomed Biotechnol. 2006;2006(3):12129. doi: 10.1155/JBB/2006/12129. J Biomed Biotechnol. 2006. PMID: 17047298 Free PMC article.

5

Proteasome or calpain inhibition does not alter cellular tau levels in neuroblastoma cells or primary neurons.

Brown MR, Bondada V, Keller JN, Thorpe J, Geddes JW. Brown MR, et al. Among authors: keller jn. J Alzheimers Dis. 2005 Feb;7(1):15-24. doi: 10.3233/jad-2005-7103. J Alzheimers Dis. 2005. PMID: 15750211

6

Recruitment methods and yield rates for a multisite clinical trial exploring risk reduction for Alzheimer's disease (rrAD).

Szabo-Reed AN, Hall T, Vidoni ED, Van Sciver A, Sewell M, Burns JM, Cullum CM, Gahan WP, Hynan LS, Kerwin DR, Rossetti H, Stowe AM, Vongpatanasin W, Zhu DC, Zhang R, Keller JN, Binder EF. Szabo-Reed AN, et al. Among authors: keller jn. Alzheimers Dement (N Y). 2023 Oct 14;9(4):e12422. doi: 10.1002/trc2.12422. eCollection 2023 Oct-Dec. Alzheimers Dement (N Y). 2023. PMID: 37841653 Free PMC article.

7

Trial of Solanezumab in Preclinical Alzheimer's Disease.

Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS; A4 Study Team. Sperling RA, et al. N Engl J Med. 2023 Sep 21;389(12):1096-1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17. N Engl J Med. 2023. PMID: 37458272 Free PMC article. Clinical Trial.

8

Safety and Tolerability of Whole Soybean Products: A Dose-Escalating Clinical Trial in Older Adults with Obesity.

Rebello CJ, Boué S, Levy RJ Jr, Puyau R, Beyl RA, Greenway FL, Heiman ML, Keller JN, Reynolds CF 3rd, Kirwan JP. Rebello CJ, et al. Among authors: keller jn. Nutrients. 2023 Apr 16;15(8):1920. doi: 10.3390/nu15081920. Nutrients. 2023. PMID: 37111139 Free PMC article. Clinical Trial.

9

Evaluation of noise regression techniques in resting-state fMRI studies using data of 434 older adults.

Scheel N, Keller JN, Binder EF, Vidoni ED, Burns JM, Thomas BP, Stowe AM, Hynan LS, Kerwin DR, Vongpatanasin W, Rossetti H, Cullum CM, Zhang R, Zhu DC. Scheel N, et al. Among authors: keller jn. Front Neurosci. 2022 Oct 19;16:1006056. doi: 10.3389/fnins.2022.1006056. eCollection 2022. Front Neurosci. 2022. PMID: 36340768 Free PMC article.

10

Driving Performance in Older Adults: Current Measures, Findings, and Implications for Roadway Safety.

Toups R, Chirles TJ, Ehsani JP, Michael JP, Bernstein JPK, Calamia M, Parsons TD, Carr DB, Keller JN. Toups R, et al. Among authors: keller jn. Innov Aging. 2022 Jan 7;6(1):igab051. doi: 10.1093/geroni/igab051. eCollection 2022. Innov Aging. 2022. PMID: 35028434 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

201 results

Search Page